Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cadieux, C.
Right arrow Articles by Nepveu, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cadieux, C.
Right arrow Articles by Nepveu, A.
[Cancer Research 66, 9492-9501, October 1, 2006]
© 2006 American Association for Cancer Research


Cell, Tumor, and Stem Cell Biology

Transgenic Mice Expressing the p75 CCAAT-Displacement Protein/Cut Homeobox Isoform Develop a Myeloproliferative Disease–Like Myeloid Leukemia

Chantal Cadieux1,2, Sylvie Fournier5, Alan C. Peterson1,3,4,6, Christian Bédard9,10, Barry J. Bedell7,8 and Alain Nepveu1,2,3,4

1 Molecular Oncology Group, McGill University Health Center, Departments of 2 Biochemistry, 3 Oncology, 4 Medicine, 5 Microbiology and Immunology, 6 Human Genetics, and 7 Pathology, McGill University; 8 McConnell Brain Imaging Centre, Montreal Neurological Institute; and Departments of 9 Pathology and 10 Microbiology, Faculty of Veterinary Medicine, Université de Montréal, Montreal, Quebec, Canada

Requests for reprints: Alain Nepveu, Molecular Oncology Group, McGill University, 687 Pine Avenue West, Room H5.21, Montreal, Quebec, Canada H3A 1A1. Phone: 514-934-1934 ext. 35842; Fax: 514-843-1478; E-mail: alain.nepveu{at}mcgill.ca.

The p75 CCAAT-displacement protein/Cut homeobox (CDP/Cux) isoform was previously reported to be overexpressed in human breast cancers. To investigate its oncogenic potential, we engineered two transgenic mouse lines expressing p75 CDP/Cux under the control of the mouse mammary tumor virus-long terminal repeat. The FVB strain of mouse is generally used in the generation of mouse models for breast cancer. The transgene was introduced into the hprt locus of 129/Ola embryonic stem cells and, following germ line passage, was backcrossed onto the FVB and C57BL/6 mouse strains. Here, we describe the phenotype of p75 CDP/Cux transgenic virgin female mice of the first backcross generations. We report that after a long latency period, ~33% of mice from two independent transgenic lines and from backcrosses into either the FVB or the C57BL/6 strains succumbed to a similar disease characterized by splenomegaly, hepatomegaly, and frequent infiltration of leukocytes into nonhematopoietic organs like the kidneys and lungs. Although an excess of B or T cells was observed in three diseased mice, in 17 other cases, histologic and flow cytometry analyses revealed the expansion of a population of neutrophils in the blood, spleen, and bone marrow. The increase in neutrophils correlated with signs of anemia and thrombocytopenia, whereas there was no indication of a reactive process. Therefore, p75 CDP/Cux transgenic mice displayed heightened susceptibility to a disease defined as a myeloproliferative disease–like myeloid leukemia. These results indicate that the overexpression of p75 CDP/Cux could alter homeostasis in the hematopoietic compartment. (Cancer Res 2006; 66(19): 9492-501)




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C. Cadieux, R. Harada, M. Paquet, O. Cote, M. Trudel, A. Nepveu, and M. Bouchard
Polycystic Kidneys Caused by Sustained Expression of Cux1 Isoform p75
J. Biol. Chem., May 16, 2008; 283(20): 13817 - 13824.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
M. Truscott, R. Harada, C. Vadnais, F. Robert, and A. Nepveu
p110 CUX1 Cooperates with E2F Transcription Factors in the Transcriptional Activation of Cell Cycle-Regulated Genes
Mol. Cell. Biol., May 15, 2008; 28(10): 3127 - 3138.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
B. Goulet, Y. Markovic, L. Leduy, and A. Nepveu
Proteolytic Processing of Cut Homeobox 1 by Neutrophil Elastase in the MV4;11 Myeloid Leukemia Cell Line
Mol. Cancer Res., April 1, 2008; 6(4): 644 - 653.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
R. Harada, C. Vadnais, L. Sansregret, L. Leduy, G. Berube, F. Robert, and A. Nepveu
Genome-wide location analysis and expression studies reveal a role for p110 CUX1 in the activation of DNA replication genes
Nucleic Acids Res., January 17, 2008; 36(1): 189 - 202.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
B. Goulet, L. Sansregret, L. Leduy, M. Bogyo, E. Weber, S. S. Chauhan, and A. Nepveu
Increased Expression and Activity of Nuclear Cathepsin L in Cancer Cells Suggests a Novel Mechanism of Cell Transformation
Mol. Cancer Res., September 1, 2007; 5(9): 899 - 907.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.